secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105011
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Q2 net loss $12.3M; positive Phase 2b CORAL results for Haduvio in IPF cough
--------------------------------------------------------------------------------

- Haduvio met primary endpoint with 60.2% cough reduction (108 mg BID) vs 16.9% placebo (p<0.0001).
- LCQ Total Score increased 3.4 points (108 mg) and 3.7 points (54 mg); 1.3-point increase is clinically meaningful.
- Completed $115M underwritten offering; cash and securities $203.9M, runway into 2029.
- R&D expenses $9.4M (down from $10.0M); G&A $4.3M (up from $3.3M); net loss $12.3M.
- Plans to request End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 start expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/0000950170-25-105011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/trvi-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer